The relation between distant metastasis and genetic change type in stage IV lung adenocarcinoma patients at diagnosis. (12th October 2020)

• Record Type: Journal Article
• Authors: Ermin, Sinem; Batum, Özgür; Saka Güvenç, Merve; Diniz, Gülden; Ayrancı, Aysu; Erdoğan, Kadri Murat; Yücel, Nur; Yıldırım, Eylem; Özdemir, Taha Reşid; Hacar, Alev Gülşah; Güldaval, Filiz; Koç, Altuğ; Aydoğdu, Zekiye; Balcı, Günseli; Özyılmaz, Berk; Akşit Yaşar, Hacer; Özer Kaya, Özge; Gayaf, Mine; Kırbıyık, Özgür; Aksel, Nimet; Kutbay, Yaşar Bekir; Ursavaş, Tuba Nihal; Karadeniz, Gülistan; Polat, Gülru; Kömürcüoğlu, Berna; Çırak, Ali Kadri; Yılmaz, Ufuk
• Is Part Of: Clinical respiratory journal. Volume 15:Number 2(2021)
• Page Start: 196
• Page End: 202
• Publication Date: 2020-10-12
• Subjects: lung adenocarcinoma -- metastasis -- mutation type -- organ; Respiratory organs -- Diseases -- Periodicals; Respiratory organs -- Periodicals; 616.24
• DOI: 10.1111/crj.13284
• Languages: English
• ISSNs: 1752-6981

Abstract

Abstract: Introduction: Brain metastasis prevalence is higher in patients with positive epidermal growth factor receptor (EGFR) mutation, anaplastic lymphoma kinase (ALK) and C‐ROS oncogene 1 (ROS‐1) fusion change in lung adenocarcinoma. Objectives: The purpose of our study is to investigate the relation between the genetic change type and the initial distant metastasis in stage IV lung adenocarcinoma patients with genetic changes. Methods: The study was conducted between January 2007 and December 2018 in a retrospective fashion with patients who had lung cancer diagnosed as stage IV adenocarcinoma. The relation between genetic mutation change (EGFR, ALK or ROS‐1) and distant metastasis was analysed. Results: A total of 845 patients were included in the study. The median age was 62 (28‐88). It was determined that lung and pleura metastases were more frequent at a significant level in patients with positive EGFR mutation ( P = 0.032, P = 0.004, respectively). In patients with positive ALK fusion change, pleura metastasis was determined to be more frequent ( P = 0.001). Multiple metastases were determined to be significantly more in patients with positive ALK fusion change than single metastasis ( P = 0.02). Conclusion: In patients with EGFR mutant lung adenocarcinoma, lung and pleura metastasis is more frequent and pleura metastasis is more frequent in ALK positive adenocarcinoma. Additionally, multiple organ metastases are higher in ALK positive lung adenocarcinoma.